NorthWest Biotherapeutics Inc (NWBO)

[CogDiss 1188X]

Recently published five-year data on Keytruda in Non-small cell lung cancer patients:

Newly presented five-year data showed that nearly twice as many patients on Keytruda were alive, compared with those who received chemotherapy (31.9% vs. 16.3%). Keytruda-treated patients also lived twice as long (26.3 months vs. 13.4 months) and a median of two months longer without disease progression (7.7 vs. 5.5 months), compared with those on chemo.

https://immuno-oncologynews.com/2020/09/28/first-line-keytruda-doubles-5-year-survival-in-certain-lung-cancer-patients-keynote-trial-data-show/